Korea Steps Up Efforts To Contain MERS Outbreak
This article was originally published in PharmAsia News
The outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) in South Korea is worsening, with the number of confirmed cases and fatalities continuing to climb. Struggling to contain the spread of the disease, the central government has announced it will step up efforts with provincial authorities, the private sector, the military and schools to ease the situation.
You may also be interested in...
Hanmi partner Athenex has had a US complete response letter for its oral paclitaxel plus encequidar product for the treatment of metastatic breast cancer, amid concerns of safety risks associated with an increase in neutropenia-related sequelae. While the decision marks another setback for Hanmi in the US, Athenex is aiming to resolve the issues.
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.
Amid the highly successful launch of COVID-19 vaccines using the technology by Pfizer/BioNTech and Moderna, South Korean bioventure OliX Pharmaceuticals is diversifying into the mRNA field by establishing a new subsidiary that focuses on R&D into new vaccines and therapeutics using the platform.